COMP <GO>
HCM vs JNJ // PIOTROSKI F-SCORE QUALITY
HUTCHMED (China) Limited (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: HCM 2
— JNJ 8
▲ PIOTROSKI F-SCORE QUALITY LEADER: JNJ
LAST: $13.59 (+2.03%) • MKT CAP: $2.37B
piotroski-score
4/9
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCM VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCM | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.50% | 25.50% | -28.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.32% | 2.97% | -6.29 | JNJ | /fcf-yield <GO> |
| Operating Margin | -7.10% | 34.70% | -41.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.50% | +39.50 | HCM | /net-margins <GO> |
| Revenue Growth (YoY) | -13.00% | 6.00% | -19.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.63 | 5.59 | -1.96 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.0 | 62.1 | -15.10 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.8x | 23.0x | -18.20 | HCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.37B | $662.49B | -$660.12B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCM REV | JNJ REV | HCM GROSS % | JNJ GROSS % | HCM FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $548.5M | $94.19B | 38.7% | 67.9% | -$78.8M | $19.70B |
| FY 2024 | $630.2M | $88.82B | 44.6% | 69.1% | -$17.4M | $19.84B |
| FY 2023 | $838.0M | $85.16B | — | — | $219.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCM // BETA —
JNJ // BETA 1.08